Sage Mountain Advisors LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Sage Mountain Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 913 shares of the biopharmaceutical company’s stock, valued at approximately $514,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. PGGM Investments boosted its holdings in Regeneron Pharmaceuticals by 159.7% during the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after buying an additional 51,900 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after buying an additional 6,073 shares in the last quarter. Generate Investment Management Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $6,300,000. Hudson Value Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $398,000. Finally, Robeco Institutional Asset Management B.V. boosted its stake in shares of Regeneron Pharmaceuticals by 153.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after acquiring an additional 73,176 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 8,431 shares of company stock worth $5,733,521 in the last quarter. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Up 2.1%

Shares of Regeneron Pharmaceuticals stock opened at $749.33 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a market cap of $78.75 billion, a P/E ratio of 17.94, a P/E/G ratio of 1.92 and a beta of 0.39. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $752.97 and a 200 day moving average price of $640.77.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $12.46 EPS. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on REGN shares. BMO Capital Markets boosted their target price on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Scotiabank lifted their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Cantor Fitzgerald boosted their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Royal Bank Of Canada upped their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Finally, Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $791.05.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.